Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.49
RGEN's Cash-to-Debt is ranked lower than
76% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. RGEN: 1.49 )
Ranked among companies with meaningful Cash-to-Debt only.
RGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.47  Med: No Debt Max: No Debt
Current: 1.49
Equity-to-Asset 0.62
RGEN's Equity-to-Asset is ranked lower than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RGEN: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
RGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.91 Max: 0.98
Current: 0.62
0.5
0.98
Debt-to-Equity 0.51
RGEN's Debt-to-Equity is ranked lower than
71% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. RGEN: 0.51 )
Ranked among companies with meaningful Debt-to-Equity only.
RGEN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.11 Max: 0.57
Current: 0.51
0
0.57
Interest Coverage 2.82
RGEN's Interest Coverage is ranked lower than
93% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RGEN: 2.82 )
Ranked among companies with meaningful Interest Coverage only.
RGEN' s Interest Coverage Range Over the Past 10 Years
Min: 2.82  Med: 430.13 Max: 3988
Current: 2.82
2.82
3988
Piotroski F-Score: 5
Altman Z-Score: 10.75
Beneish M-Score: -1.17
WACC vs ROIC
8.81%
25.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 15.71
RGEN's Operating Margin % is ranked higher than
85% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. RGEN: 15.71 )
Ranked among companies with meaningful Operating Margin % only.
RGEN' s Operating Margin % Range Over the Past 10 Years
Min: -27.5  Med: 15.88 Max: 186.01
Current: 15.71
-27.5
186.01
Net Margin % 15.61
RGEN's Net Margin % is ranked higher than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. RGEN: 15.61 )
Ranked among companies with meaningful Net Margin % only.
RGEN' s Net Margin % Range Over the Past 10 Years
Min: -19.38  Med: 12.03 Max: 192.3
Current: 15.61
-19.38
192.3
ROE % 10.21
RGEN's ROE % is ranked higher than
85% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. RGEN: 10.21 )
Ranked among companies with meaningful ROE % only.
RGEN' s ROE % Range Over the Past 10 Years
Min: -6.01  Med: 7.99 Max: 82.79
Current: 10.21
-6.01
82.79
ROA % 6.08
RGEN's ROA % is ranked higher than
85% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. RGEN: 6.08 )
Ranked among companies with meaningful ROA % only.
RGEN' s ROA % Range Over the Past 10 Years
Min: -5.6  Med: 6.72 Max: 75.79
Current: 6.08
-5.6
75.79
ROC (Joel Greenblatt) % 45.29
RGEN's ROC (Joel Greenblatt) % is ranked higher than
91% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. RGEN: 45.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -97.28  Med: 50.1 Max: 1148.92
Current: 45.29
-97.28
1148.92
3-Year Revenue Growth Rate 13.40
RGEN's 3-Year Revenue Growth Rate is ranked higher than
66% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. RGEN: 13.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.3  Med: 13.2 Max: 45.6
Current: 13.4
-52.3
45.6
3-Year EBITDA Growth Rate -8.90
RGEN's 3-Year EBITDA Growth Rate is ranked lower than
63% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. RGEN: -8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -68.2  Med: 3.8 Max: 115.3
Current: -8.9
-68.2
115.3
3-Year EPS without NRI Growth Rate -12.10
RGEN's 3-Year EPS without NRI Growth Rate is ranked lower than
64% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. RGEN: -12.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -73  Med: 6.7 Max: 108
Current: -12.1
-73
108
GuruFocus has detected 5 Warning Signs with Repligen Corp $RGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RGEN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

RGEN Guru Trades in Q3 2016

Joel Greenblatt 140,516 sh (+135.30%)
Chuck Royce 199,000 sh (+25.16%)
Paul Tudor Jones Sold Out
Jim Simons 1,077,700 sh (-4.19%)
Columbia Wanger 559,471 sh (-30.14%)
» More
Q4 2016

RGEN Guru Trades in Q4 2016

Joel Greenblatt 129,559 sh (-7.80%)
Jim Simons 891,600 sh (-17.27%)
Columbia Wanger 294,991 sh (-47.27%)
Chuck Royce 98,000 sh (-50.75%)
» More
Q1 2017

RGEN Guru Trades in Q1 2017

Columbia Wanger Sold Out
Joel Greenblatt 127,064 sh (-1.93%)
Chuck Royce 70,000 sh (-28.57%)
Jim Simons 628,400 sh (-29.52%)
» More
Q2 2017

RGEN Guru Trades in Q2 2017

Paul Tudor Jones 23,752 sh (New)
Chuck Royce 70,000 sh (unchged)
Joel Greenblatt 121,625 sh (-4.28%)
Jim Simons 299,400 sh (-52.36%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Reduce -4.28%$33.64 - $45.34 $ 44.2017%121,625
Joel Greenblatt 2017-03-31 Reduce -1.93%$28.82 - $35.2 $ 44.2040%127,064
Joel Greenblatt 2016-12-31 Reduce -7.80%$26.64 - $33.98 $ 44.2043%129,559
Joel Greenblatt 2016-09-30 Add 135.30%0.03%$26.06 - $33.42 $ 44.2046%140,516
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ARRY, NAS:CORT, NYSE:CBM, NAS:INSM, NAS:MYOK, NAS:AKCA, NYSE:EBS, NAS:BPMC, NAS:XLRN, NAS:FOLD, NAS:INVA, NAS:HALO, NYSE:XON, NAS:SAGE, NAS:RARE, NAS:ICPT, NYSE:BHVN, NAS:LXRX, NAS:DVAX, NAS:IMMU » details
Traded in other countries:RGN.Germany,
Headquarter Location:USA
Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.

Repligen Corp is a bioprocessing company that develops, produces and commercializes innovative biologic drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's total revenue is generated in Sweden, followed by the United States, United Kingdom, and other regions.

Ratios

vs
industry
vs
history
PE Ratio 88.22
RGEN's PE Ratio is ranked lower than
86% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. RGEN: 88.22 )
Ranked among companies with meaningful PE Ratio only.
RGEN' s PE Ratio Range Over the Past 10 Years
Min: 3.19  Med: 63.53 Max: 534
Current: 88.22
3.19
534
Forward PE Ratio 61.73
RGEN's Forward PE Ratio is ranked lower than
89% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. RGEN: 61.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 88.22
RGEN's PE Ratio without NRI is ranked lower than
86% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. RGEN: 88.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
RGEN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.19  Med: 67.19 Max: 99999999.99
Current: 88.22
3.19
99999999.99
PB Ratio 7.84
RGEN's PB Ratio is ranked lower than
77% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. RGEN: 7.84 )
Ranked among companies with meaningful PB Ratio only.
RGEN' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 3.02 Max: 12.19
Current: 7.84
1.42
12.19
PS Ratio 13.46
RGEN's PS Ratio is ranked lower than
52% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. RGEN: 13.46 )
Ranked among companies with meaningful PS Ratio only.
RGEN' s PS Ratio Range Over the Past 10 Years
Min: 2.73  Med: 6.87 Max: 20.45
Current: 13.46
2.73
20.45
Price-to-Operating-Cash-Flow 326.75
RGEN's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. RGEN: 326.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RGEN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.14  Med: 35.85 Max: 99999999.99
Current: 326.75
3.14
99999999.99
EV-to-EBIT 103.92
RGEN's EV-to-EBIT is ranked lower than
87% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. RGEN: 103.92 )
Ranked among companies with meaningful EV-to-EBIT only.
RGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -633.3  Med: 16.15 Max: 650.3
Current: 103.92
-633.3
650.3
EV-to-EBITDA 77.25
RGEN's EV-to-EBITDA is ranked lower than
86% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. RGEN: 77.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8133.7  Med: 21.8 Max: 3669.8
Current: 77.25
-8133.7
3669.8
EV-to-Revenue 16.36
RGEN's EV-to-Revenue is ranked higher than
51% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. RGEN: 16.36 )
Ranked among companies with meaningful EV-to-Revenue only.
RGEN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 5.1 Max: 19.7
Current: 16.36
1.6
19.7
PEG Ratio 2.18
RGEN's PEG Ratio is ranked lower than
62% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. RGEN: 2.18 )
Ranked among companies with meaningful PEG Ratio only.
RGEN' s PEG Ratio Range Over the Past 10 Years
Min: 2.18  Med: 7.16 Max: 8.07
Current: 2.18
2.18
8.07
Shiller PE Ratio 111.64
RGEN's Shiller PE Ratio is ranked lower than
76% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. RGEN: 111.64 )
Ranked among companies with meaningful Shiller PE Ratio only.
RGEN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 44.76  Med: 85.53 Max: 470
Current: 111.64
44.76
470
Current Ratio 11.86
RGEN's Current Ratio is ranked higher than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. RGEN: 11.86 )
Ranked among companies with meaningful Current Ratio only.
RGEN' s Current Ratio Range Over the Past 10 Years
Min: 1.55  Med: 8.55 Max: 44.57
Current: 11.86
1.55
44.57
Quick Ratio 10.28
RGEN's Quick Ratio is ranked higher than
85% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. RGEN: 10.28 )
Ranked among companies with meaningful Quick Ratio only.
RGEN' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 7.7 Max: 43.88
Current: 10.28
1.4
43.88
Days Inventory 174.07
RGEN's Days Inventory is ranked lower than
63% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. RGEN: 174.07 )
Ranked among companies with meaningful Days Inventory only.
RGEN' s Days Inventory Range Over the Past 10 Years
Min: 87.98  Med: 151.71 Max: 174.07
Current: 174.07
87.98
174.07
Days Sales Outstanding 71.23
RGEN's Days Sales Outstanding is ranked higher than
55% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. RGEN: 71.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.73  Med: 25.43 Max: 71.23
Current: 71.23
6.73
71.23
Days Payable 49.43
RGEN's Days Payable is ranked lower than
66% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. RGEN: 49.43 )
Ranked among companies with meaningful Days Payable only.
RGEN' s Days Payable Range Over the Past 10 Years
Min: 24.96  Med: 58.01 Max: 161.29
Current: 49.43
24.96
161.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
RGEN's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. RGEN: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.2  Med: -4.1 Max: 0.3
Current: -2
-18.2
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 55.14
RGEN's Price-to-Net-Cash is ranked lower than
92% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. RGEN: 55.14 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RGEN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.93  Med: 5.89 Max: 57.58
Current: 55.14
1.93
57.58
Price-to-Net-Current-Asset-Value 19.26
RGEN's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. RGEN: 19.26 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RGEN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.59  Med: 4.57 Max: 20.11
Current: 19.26
1.59
20.11
Price-to-Tangible-Book 14.90
RGEN's Price-to-Tangible-Book is ranked lower than
85% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. RGEN: 14.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.95  Med: 3.28 Max: 15.56
Current: 14.9
0.95
15.56
Price-to-Intrinsic-Value-Projected-FCF 4.93
RGEN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. RGEN: 4.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RGEN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.2 Max: 6.15
Current: 4.93
0.69
6.15
Price-to-Median-PS-Value 1.96
RGEN's Price-to-Median-PS-Value is ranked lower than
81% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. RGEN: 1.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 1.03 Max: 10.33
Current: 1.96
0.17
10.33
Price-to-Peter-Lynch-Fair-Value 8.05
RGEN's Price-to-Peter-Lynch-Fair-Value is ranked lower than
84% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. RGEN: 8.05 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
RGEN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.24  Med: 4.79 Max: 29.31
Current: 8.05
0.24
29.31
Price-to-Graham-Number 7.64
RGEN's Price-to-Graham-Number is ranked lower than
89% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. RGEN: 7.64 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RGEN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.54  Med: 4.2 Max: 11.18
Current: 7.64
0.54
11.18
Earnings Yield (Greenblatt) % 0.97
RGEN's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. RGEN: 0.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.2  Med: 1.4 Max: 9.9
Current: 0.97
-11.2
9.9
Forward Rate of Return (Yacktman) % 11.77
RGEN's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. RGEN: 11.77 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RGEN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -39.1  Med: 4.7 Max: 23.6
Current: 11.77
-39.1
23.6

More Statistics

Revenue (TTM) (Mil) $113.32
EPS (TTM) $ 0.50
Beta1.11
Short Percentage of Float9.96%
52-Week Range $26.16 - 46.81
Shares Outstanding (Mil)43.05

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 124 145
EPS ($) 0.57 0.72
EPS without NRI ($) 0.57 0.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.00%
Dividends per Share ($)
» More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen Announces Analyst Day and Webcast Sep 15 2017 
Repligen to Present at Baird’s 2017 Global Healthcare Conference Aug 30 2017 
Repligen to Report Second Quarter 2017 Financial Results Jul 27 2017 
Repligen Corporation and Spectrum, Inc. to Join Forces Jun 23 2017 
Repligen to Present at Jefferies’ 2017 Global Annual Healthcare Conference May 31 2017 
Repligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference May 24 2017 
Repligen to Present at Bank of America Merrill Lynch 2017 Healthcare Conference May 09 2017 
Repligen to Report First Quarter 2017 Financial Results Apr 21 2017 
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 

More From Other Websites
Repligen Announces Analyst Day and Webcast Sep 15 2017
See what the IHS Markit Score report has to say about Repligen Corp. Sep 12 2017
Have Investors Already Priced In Repligen Corporation’s (RGEN) Growth? Sep 08 2017
Repligen to Present at Baird’s 2017 Global Healthcare Conference Aug 30 2017
Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : August 25, 2017 Aug 25 2017
Repligen Corp. – Value Analysis (NASDAQ:RGEN) : August 14, 2017 Aug 14 2017
Edited Transcript of RGEN earnings conference call or presentation 3-Aug-17 12:30pm GMT Aug 13 2017
Repligen beats Street 2Q forecasts Aug 03 2017
Repligen Reports Second Quarter 2017 Financial Results Aug 03 2017
Investor Network: Repligen Corporation to Host Earnings Call Aug 03 2017
Repligen Corp. breached its 50 day moving average in a Bearish Manner : RGEN-US : July 31, 2017 Jul 31 2017
Repligen to Report Second Quarter 2017 Financial Results Jul 27 2017
Top Ranked Momentum Stocks to Buy for July 3rd Jul 03 2017
Repligen Corporation Prices Public Offering of Shares of Common Stock Jun 27 2017
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock Jun 26 2017
Corporate News Blog - Repligen Corp. and Spectrum Merge to Form Leader in Filtration for... Jun 26 2017
Repligen to buy filtration company Spectrum for $359 million in cash and stock Jun 23 2017
Repligen Corporation and Spectrum, Inc. to Join Forces Jun 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}